Answers are grounded in this paper and cite their sources.
In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
No takes yet. Share an insight, caveat, or question.
Murthy et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: